J&J
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
Quanterix Signs Licensing Deal With J&J for Blood-Based Alzheimer's Assay Development
Quanterix gained rights to Johnson and Johnson's phosphorylated-tau 217 antibodies and assay designs in research test kits and an LDT.
UK Launches Public-Private iDx-Lung Consortium to Improve Early Detection of Lung Cancers
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
AnchorDx, Johnson & Johnson Collaborate on Early-Stage Lung Cancer Diagnosis Study
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.